Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
暂无分享,去创建一个
Kylie L. Gorringe | A. Talhouk | A. Mes-Masson | M. Köbel | D. Provencher | C. Gilks | M. Carey | N. Hacker | I. Campbell | K. Pishas | K. Gorringe | D. Chiu | D. Cheasley | Abhimanyu Nigam | Marta Llauradó Fernández | Hannah Kim | A. Dawson | J. Hoenisch | M. Bittner | Madawa W Jayawardana | K. I. Pishas
[1] R. L. Hollis,et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification , 2021, npj Precision Oncology.
[2] J. Copland,et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers , 2020, ESMO Open.
[3] Kylie L. Gorringe,et al. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.
[4] V. Kristensen,et al. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer , 2020, Breast Cancer Research and Treatment.
[5] D. Huntsman,et al. Low-grade serous ovarian cancer: State of the science. , 2020, Gynecologic oncology.
[6] A. Talhouk,et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. , 2020, Gynecologic oncology.
[7] A. Sood,et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. , 2019, Gynecologic oncology.
[8] Olga Tanaseichuk,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[9] C. Denkert,et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. , 2019, Human pathology.
[10] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[11] C. Cole,et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.
[12] Sebastian M. Armasu,et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study , 2018, The journal of pathology. Clinical research.
[13] C. Le Page,et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.
[14] Dale W. Garsed,et al. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. , 2017, Cancer research.
[15] E. Martinelli,et al. Hormone receptor expression profile of low-grade serous ovarian cancers. , 2017, Gynecologic oncology.
[16] N. Ahmed,et al. Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling , 2017, Scientific Reports.
[17] M. Köbel,et al. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications , 2017, International journal of molecular sciences.
[18] D. Bodurka,et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Kun Yu,et al. PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.
[20] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[21] A. Reuss,et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.
[22] P. Tauchi-Nishi,et al. The LAST guidelines in clinical practice: implementing recommendations for p16 use. , 2015, American journal of clinical pathology.
[23] Kylie L. Gorringe,et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes , 2015, Oncotarget.
[24] D. Bodurka,et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Caroline H. Diep,et al. Progesterone action in breast, uterine, and ovarian cancers. , 2015, Journal of molecular endocrinology.
[26] Jos Jonkers,et al. CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.
[27] A. Whittemore,et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.
[28] Caroline H. Diep,et al. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells , 2013, Cell cycle.
[29] C. Le Page,et al. Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. , 2013, Biopreservation and biobanking.
[30] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[31] G. Castellano,et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. , 2012, Genes & development.
[32] D. Bodurka,et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.
[33] K. Kinzler,et al. Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.
[34] D. Bodurka,et al. Clinicodemographic factors influencing outcomes in patients with low‐grade serous ovarian carcinoma , 2011, Cancer.
[35] K. Darvishi. Application of Nexus Copy Number Software for CNV Detection and Analysis , 2010, Current protocols in human genetics.
[36] Shan Wang-Gohrke,et al. ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[37] A. Sood,et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.
[38] Mike Tyers,et al. BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..
[39] M. Y. Kim,et al. NAD+-Dependent Modulation of Chromatin Structure and Transcription by Nucleosome Binding Properties of PARP-1 , 2004, Cell.
[40] Robert W. Rudd,et al. OF THE STATE OF THE SCIENCE * , 2002 .
[41] John Van Hoewyk,et al. A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .
[42] K. Horwitz,et al. Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding domain of progesterone receptors. , 2000, Journal of molecular endocrinology.
[43] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .